Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor

Toxicologic Pathology

Volumn 33, Issue 4, 2005, Pages 449-455

  Brown, Alan P ^a   Courtney, Cynthia L ^a   King, Lena M ^b   Groom, Stephen C ^b   Graziano, Michael J ^a  

^a PFIZER INC   (United States)

^b NONE

Author keywords

Angiogenesis inhibitor; Fibroblast growth factor; Hyperphosphatemia; Skeletal toxicity; Vascular endothelial growth factor

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; FIBROBLAST GROWTH FACTOR RECEPTOR; PD 176067; PHOSPHORUS; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CARTILAGE CELL; CELL PROLIFERATION; CHONDRODYSPLASIA; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; HYPERPHOSPHATEMIA; MINERALIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; TOXICITY;

ADMINISTRATION, ORAL; AGE FACTORS; ANGIOGENESIS INHIBITORS; ANIMALS; CALCINOSIS; CELL PROLIFERATION; CHONDROCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FEMALE; FIBROBLAST GROWTH FACTOR 1; HETEROCYCLIC COMPOUNDS, 2-RING; OSTEOCHONDRODYSPLASIAS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR PROTEIN-TYROSINE KINASES; TOXICITY TESTS;

ANIMALIA;

EID: 22244492038     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230590961845     Document Type: Article

References (26)

1. Aviezer, D., Golembo, M., and Yayon, A. (2003). Fibroblast growth factor receptor-3 as a therapeutic target for achondroplasia - genetic short limbed dwarfism. Curr Drug Targets 4, 353-65.
2. Baron, J., Klein, K. O., Yanovski, J. A., Novosad, J. A., Bacher, J. D., Bolander, M. E., and Cutler, G. B. (1994). Induction of growth plate cartilage ossification by basic fibroblast growth factor. Endocrinology 135, 2790-3.
3. Block, G. A. (2000). Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol 54, 318-24.
4. Block, G. A. (2001). Control of serum phosphorus: implications for coronary artery calcifications and calcific uremic arteriolopathy (calciphylaxis). Curr Op Nephrol Hypert 10, 741-7.
5. Courtney, C. L., Datta, K., Brown, A. P., and Graziano, M. J. (2003). Drug-induced physeal dysplasia in dogs following administration of PD176067, an inhibitor of basic fibroblast growth factor receptor tyrosine kinase. Toxicol Pathol 31, 139.
6. Cross, M. J., and Claesson-Welsh, L. (2001). FGF and VEGF function in angiogenesis: signaling pathways, biological responses and therapeutic inhibition. Trends Pharm Sci 22(4), 201-7.
7. Datta, K., Graziano, M. J., and Courtney, C. L. (2003). Toxicity of the fibroblast growth factor inhibitor, PD176067, in juvenile and adult dogs. Toxicologist 72(S-1), 386.
8. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A., and Leder, P. (1996). Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911-21.
9. Evans, G. O. (1996). General enzymology. In Animal Clinical Chemistry, A Primer for Toxicologists, pp 59-70. Taylor and Francis, New York.
10. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. New Engl J Med 285, 1182-6.
11. Folkman, J., Browder, T., and Palmblad, J. (2001). Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 86, 23-33.
12. Folkman, J., and Klagsbrun, M. (1987). Angiogenic factors. Science 235, 442-7.
13. Gerber, H. P., Vu, T. H., Ryan, A. M., Kowalski, J., Werb, Z., and Ferrera, N. (1999). VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5, 623-8.
14. Grant, R. A., Gillman, T., and Hathorn, M. (1963). Prolonged chemical and histochemical changes associated with widespread calcification of soft tissues following brief acute calciferol intoxication. Br J Exp Path 44(2), 220-32.
15. Harper, J., and Kalgsbrun, M. (1999). Cartilage to bone-angiogenesis leads the way. Nat Med 5, 617-8.
16. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 350(23), 2335-42.
17. Kamio, A., Taguchi, T., Shiraishi, M., Shitama, K., Fukushima, K., and Takebayashi, S. (1979). Vitamin D sclerosis in rats. Acta Path Jap 29(4), 545-62.
18. Mohammadi, M., Froum, S., Hamby, J. M., Schroeder, M. C., Panek, R. L., Lu, G. H., Eliseenkova, A. V., Green, D., Schlessinger, J., and Hubbard, S. R. (1998). Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 17(20), 5896-904.
19. 3, tacalcitol, and calcipotriol after topical treatment in rats. J Inv Dermatol Symp Proceed 1, 60-3.
20. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13, 9-22.
21. Parke-Davis, Warner-Lambert, Co. (2000). Profile of PD0176067-0002, lead compound candidate, cancer antiangiogenesis. Internal publication, Ann Arbor, MI, USA.
22. Pluda, J. M. (1997). Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Sem Oncol 24(2), 203-18.
23. Rosenblum, I. Y., Black, H. E., and Ferrel, J. F. (1977). The effects of various diphosphonates on a rat model of cardiac calciphylaxis. Calcif Tiss Res 23, 151-59.
24. Ryan, A. M., Eppler, D. B., Hagler, K. E., Bruner, R. H., Thomford, P. J., Hall, R. L., Shopp, G. M., and O'Neill, C. A. (1999). Preclinical safety evaluation of rhuMabVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 27, 78-86.
25. Wedge, S. R., Ogilvie, D. J., Dukes, M., Kendrew, J., Curwen, J. O., Hennequin, L. F., Thomas, A. P., Stokes, E. S. E., Curry, B., Richmond, G. H. P., and Wadsworth, P. F. (2000). ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60, 970-5.
26. Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., and Rosenberg, S. A. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New Engl J Med 349(5), 427-34.